Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Short-Course Radiotherapy Combined With mFOLFOX6, PD-1 Antibody and Cetuximab (for RAS/BRAF Wild-Type)/Bevacizumab (for RAS/BRAF Mutant) in High-Risk pMMR/MSS Rectal Adenocarcinoma: a Phase III Randomized Controlled Trial

NCT07549399 is registered in ClinicalTrials.gov with Sixth Affiliated Hospital, Sun Yat-sen University as lead sponsor.

NCT NCT07549399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07549399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Short-Course Radiotherapy Combined With mFOLFOX6, PD-1 Antibody and Cetuximab (for RAS/BRAF Wild-Type)/Bevacizumab (for RAS/BRAF Mutant) in High-Risk pMMR/MSS Rectal Adenocarcinoma: a Phase III Randomized Controlled Trial
Lead sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Phase
Phase 3
Overall status
Recruiting
Start date
May 20, 2026
Completion date
April 30, 2029
Enrollment
204 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk cancer, mss, rectal adenocarcinoma